Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfram Brugger

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Seminars in Oncology|March 26, 2004
Clearing minimal residual disease with rituximab consolidation therapyWolfram Brugger
Tumori|September 18, 2010
Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximabWolfram Brugger
Seminars in Oncology|February 1, 2017
Clearing Minimal Residual Disease with Rituximab Consolidation TherapyWolfram Brugger
Seminars in Oncology|June 1, 2002
Improving outcomes in transplantationWolfram Brugger
Clinical Advances in Hematology & Oncology : H&O|March 9, 2012
Molecular marker analyses from the SATURN trialWolfram Brugger
The Oncologist|August 1, 2013
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient managementWolfram Brugger, Michele Ghielmini
Lung Cancer (Amsterdam, Netherlands)|January 28, 2012
EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatmentWolfram Brugger, Michael Thomas
European Journal of Haematology|February 2, 2010
Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximabGeorgios Papakonstantinou, Helmut Loeffler, Torsten Haferlach, et al.
Oncology Research and Treatment|May 14, 2015
[What opportunities does Immuno-oncology indicate for overarching long-term survival?]Lothar Bergmann, Wolfram Brugger, Wolfgang Herr, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2002
Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gammaAlessio Nencioni, Frank Grünebach, Anke Zobywlaski, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Seminars in Oncology|March 26, 2004
Clearing minimal residual disease with rituximab consolidation therapyWolfram Brugger
Tumori|September 18, 2010
Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximabWolfram Brugger
Seminars in Oncology|February 1, 2017
Clearing Minimal Residual Disease with Rituximab Consolidation TherapyWolfram Brugger
Seminars in Oncology|June 1, 2002
Improving outcomes in transplantationWolfram Brugger
Clinical Advances in Hematology & Oncology : H&O|March 9, 2012
Molecular marker analyses from the SATURN trialWolfram Brugger
The Oncologist|August 1, 2013
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient managementWolfram Brugger, Michele Ghielmini
Lung Cancer (Amsterdam, Netherlands)|January 28, 2012
EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatmentWolfram Brugger, Michael Thomas
European Journal of Haematology|February 2, 2010
Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximabGeorgios Papakonstantinou, Helmut Loeffler, Torsten Haferlach, et al.
Oncology Research and Treatment|May 14, 2015
[What opportunities does Immuno-oncology indicate for overarching long-term survival?]Lothar Bergmann, Wolfram Brugger, Wolfgang Herr, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2002
Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gammaAlessio Nencioni, Frank Grünebach, Anke Zobywlaski, et al.
Pageof 6